CDE Catalog

***Please contact the NINDS CDE Team (NINDSCDE@emmes.com) if you encounter any search difficulties.***

The CDE Catalog is a directory of the available NINDS CDEs. Users can search the Catalog to isolate a subset of the CDEs (e.g., all stroke-specific CDEs, etc.), and to view and download details about the CDEs.

Select any filter below to search the CDE Catalog.

For best results, clear form between searches. In addition, when specifying NeuroRehab, Sport-Related Concussion (SRC) or Traumatic Brain Injury (TBI) as the Disease, please select a Subdisease as well.

NeuroRehab Comprehensive includes all NeuroRehab CDE recommendations. NeuroRehab General includes all NeuroRehab CDE recommendations that are not disease specific. All other NeuroRehab Subdiseases include recommendations specific to existing NINDS CDE project disorders.

Choose your Time Frame for your SRC study (Acute (time of injury until 72 hours), Subacute (after 72 hours to 3 months), and Persistent/Chronic (3 months and greater post-concussion) or Comprehensive if your study falls across the study time frames.

Choose your type of TBI study (Acute Hospitalized, Concussion/Mild TBI, Moderate/Severe TBI: Rehabilitation, or Epidemiology) or Comprehensive if your study falls outside of the study types or incorporates aspects of more than one type of study.

Search Form

Displaying 226 - 250 of 708
Operations
Selected 25 rows in this page.  
The search results below can be downloaded by clicking the checkboxes on the far left side of the table. Select the header checkbox to select all CDEs listed on the first page. Then choose CDE Detailed Report from the Choose an operation dropdown menu.
CDE ID CDE Name Definition Classification CRF Name Copyrighted or trademarked Disease Name Subdisease Name
C02411 Laterality type

Laterality type relative to the anatomic site of the body examined or affected

Supplemental Grip Strength Fatigue Amyotrophic Lateral Sclerosis Amyotrophic Lateral Sclerosis
C02411 Laterality type

Laterality type relative to the anatomic site of the body examined or affected

Supplemental Pulmonary Function Amyotrophic Lateral Sclerosis Amyotrophic Lateral Sclerosis
C01519 Vital signs date and time

Date (and time, if applicable and known) the vital signs and other body measurements were taken by indicating the month, day, and year for the date and am, pm, or 24 hour clock for time

Core Vital Signs Amyotrophic Lateral Sclerosis Amyotrophic Lateral Sclerosis
C00020 Ethnicity USA category

Category of ethnicity the participant/subject most closely identifies with

Core General Core Amyotrophic Lateral Sclerosis Amyotrophic Lateral Sclerosis
C01010 Physical exam date and time

Date (and time if applicable and known) physical exam was performed

Core Physical Examination Amyotrophic Lateral Sclerosis Amyotrophic Lateral Sclerosis
C11026 Neuromuscular Exam Muscle weakness indicator

Indicator whether there is muscle weakness in the muscle or muscle group examined

Supplemental Neuromuscular Examination Amyotrophic Lateral Sclerosis Amyotrophic Lateral Sclerosis
C02003 Medication prior or concomitant ongoing indicator

Indicator of or description that the prior/concomitant medication usage is ongoing

Supplemental Prior and Concomitant Medications Amyotrophic Lateral Sclerosis Amyotrophic Lateral Sclerosis
C02411 Laterality type

Laterality type relative to the anatomic site of the body examined or affected

Supplemental Electrophysiology Amyotrophic Lateral Sclerosis Amyotrophic Lateral Sclerosis
C10626 Condition diary date and time

Date (and time, if applicable and known) the diary data are recorded

Exploratory Clinical Milestones/Events Amyotrophic Lateral Sclerosis Amyotrophic Lateral Sclerosis
C02411 Laterality type

Laterality type relative to the anatomic site of the body examined or affected

Supplemental Hand Held Dynamometry Amyotrophic Lateral Sclerosis Amyotrophic Lateral Sclerosis
C02024 Medication prior or concomitant indication text

Text describing reason for administration of a prior/concomitant (nonstudy) agent or measure. This is not the pharmacologic classification of an agent (antibiotic, analgesic, etc.), but the reason for its administration to the participant/subject

Supplemental Prior and Concomitant Medications Amyotrophic Lateral Sclerosis Amyotrophic Lateral Sclerosis
C02025 Medication prior or concomitant RXNorm code

Code for name of the prior/concomitant agent or drug administered

Supplemental Prior and Concomitant Medications Amyotrophic Lateral Sclerosis Amyotrophic Lateral Sclerosis
C00020 Ethnicity USA category

Category of ethnicity the participant/subject most closely identifies with

Core Demographics Amyotrophic Lateral Sclerosis Amyotrophic Lateral Sclerosis
C01539 Temperature measurement

Measurement of the participant's/subject's body temperature

Supplemental Vital Signs Amyotrophic Lateral Sclerosis Amyotrophic Lateral Sclerosis
C10591 Imaging phase encode direction text

Text description of the phase encode direction used in imaging technique acquisition

Exploratory Diffusion Tensor Imaging (DTI) Amyotrophic Lateral Sclerosis Amyotrophic Lateral Sclerosis
C10687 Imaging diffusion first b value

Value, in square millimeters per second, of the first b-value used in diffusion acquisition

Supplemental Diffusion Tensor Imaging (DTI) Amyotrophic Lateral Sclerosis Amyotrophic Lateral Sclerosis
C10782 Electrophysiology motor unit number estimation method used type

Type of method or technique used for MUNE (motor unit number estimation)

Supplemental Electrophysiology Amyotrophic Lateral Sclerosis Amyotrophic Lateral Sclerosis
C08245 Imaging slice count

Count representing the total number of single image planes captured during imaging acquisition

Supplemental Magnetic Resonance Imaging (MRI) Amyotrophic Lateral Sclerosis Amyotrophic Lateral Sclerosis
C08245 Imaging slice count

Count representing the total number of single image planes captured during imaging acquisition

Supplemental Functional Magnetic Resonance Imaging (fMRI) Amyotrophic Lateral Sclerosis Amyotrophic Lateral Sclerosis
C10594 Imaging parallel acquisition used indicator

Indicator of whether a parallel acquisition method is used in imaging acquisition

Exploratory Magnetic Resonance Imaging (MRI) Amyotrophic Lateral Sclerosis Amyotrophic Lateral Sclerosis
C08244 Imaging slice thickness value

Value of the thickness of the slice measured in millimeters (mm)

Supplemental Magnetic Resonance Imaging (MRI) Amyotrophic Lateral Sclerosis Amyotrophic Lateral Sclerosis
C01707 Lab test abnormality significance type

Indicator as to whether or not the abnormal lab result for the associated test was considered clinically significant for the participant/subject

Supplemental Laboratory Tests Amyotrophic Lateral Sclerosis Amyotrophic Lateral Sclerosis
C10586 Imaging bandwidth value

Value, in Hertz per pixel, of bandwidth used in imaging acquisition

Exploratory Brain Perfusion Magnetic Resonance Imaging Amyotrophic Lateral Sclerosis Amyotrophic Lateral Sclerosis
C10594 Imaging parallel acquisition used indicator

Indicator of whether a parallel acquisition method is used in imaging acquisition

Exploratory Brain Perfusion Magnetic Resonance Imaging Amyotrophic Lateral Sclerosis Amyotrophic Lateral Sclerosis
C00312 Body system category

Category or grouping used in the comprehensive assessment of a participant/subject, which includes a subjective history taking component as well as an objective based structured interview and physical examination of all the body systems

Core Medical History Amyotrophic Lateral Sclerosis Amyotrophic Lateral Sclerosis
Displaying 226 - 250 of 708

The NINDS CDE Team does not post proprietary instruments/scales recommended by the CDE Working Groups on this website. This includes, but is not limited to, copyrighted or trademarked instruments/scales. Information about recommended instruments can be found in the Notice of Copyright (NOC) documents under ‘CRF Module/Guideline’ on each disorder’s data standards page. For any questions regarding these instruments/scales please contact the corresponding owner/author. The NINDS CDE Team is not responsible for the availability or content of these external sites, nor does the NINDS CDE Team endorse, warrant or guarantee the products, services or information described or offered at these other internet sites.